- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Lobe Sciences Ltd (2): Lobe Sciences' Nov. 30 cash at $5.99-million | 1 | Stockwatch | ||
| Di | Lobe Sciences Ltd.: Lobe Sciences Reports First Quarter 2026 Results and Highlights | 229 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases... ► Artikel lesen | |
| 13.01. | Lobe Sciences Ltd (2): Lobe Sciences appoints Karakochuk as director | 1 | Stockwatch | ||
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 13.01. | Lobe Sciences Ltd.: Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors | 262 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 13, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 09.01. | Lobe Sciences Ltd (2): Lobe Sciences ends FY 2025 with cash of $5.85-million | 1 | Stockwatch | ||
| 08.01. | Lobe Sciences Ltd.: Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy | 189 | ACCESS Newswire | Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical... ► Artikel lesen | |
| 06.01. | Lobe Sciences Ltd (2): Lobe Sciences has cash of $5.85-million at Aug. 31 | 1 | Stockwatch | ||
| 06.01. | Lobe Sciences Ltd.: Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition | 280 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in... ► Artikel lesen | |
| 24.10.25 | Lobe Sciences Ltd.: Lobe Sciences Completes Debt Settlement to Improve Balance Sheet | 327 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / October 23, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies... ► Artikel lesen | |
| 09.10.25 | Lobe Sciences Ltd (2): Lobe Sciences arranges $137,130 (U.S.) debt settlement | 4 | Stockwatch | ||
| 09.10.25 | Lobe Sciences Ltd.: Lobe Sciences Improves Balance Sheet | 247 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops... ► Artikel lesen | |
| 16.09.25 | ArcStone US Corp.: Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto | 633 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 15, 2025) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical... ► Artikel lesen | |
| 10.09.25 | Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025 | 477 | ACCESS Newswire | VANCOUVER, B.C. / ACCESS Newswire / September 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 09.09.25 | Lobe Sciences Ltd.: Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors | 462 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on... ► Artikel lesen | |
| 15.08.25 | Lobe Sciences Ltd.: Lobe Sciences Announces the Closing of the Previously Announced Private Placement | 478 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company")... ► Artikel lesen | |
| 29.07.25 | Lobe Sciences Ltd.: Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes | 506 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. ("Lobe Sciences"... ► Artikel lesen | |
| 29.07.25 | Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory | 506 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases... ► Artikel lesen | |
| 17.07.25 | Lobe Sciences Ltd. Announces Debt Settlement | 462 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases... ► Artikel lesen | |
| 08.07.25 | Lobe Sciences Ltd.: Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease | 757 | ACCESS Newswire | European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease.Covers... ► Artikel lesen | |
| 18.06.25 | Lobe Sciences Ltd.: Lobe Sciences Moves Forward with Development of Conjugated Psilocin Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals | 376 | ACCESS Newswire | New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin$6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,387 | +2,38 % | BioNxt sichert sich innovative Chaperon-Technologie zur Verbesserung der oralen Dünnfilm-Wirkstoffverabreichung | VANCOUVER, BC / ACCESS Newswire /
5. Februar 2026 - BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT), ein biowissenschaftliches
Innovationsunternehmen... ► Artikel lesen | |
| ATAIBECKLEY | 3,770 | +10,56 % | Psychodelika-Aktien: Sind Bioxyne, Compass Pathways und Atai "the next big thing"? | ||
| SOL GLOBAL INVESTMENTS | 0,060 | -5,35 % | SOL Global Investments Corp.: SOL Global Announces Settlement of Outstanding Debentures | Toronto, Ontario--(Newsfile Corp. - January 21, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCD) (FSE: 9SB0) ("SOL" or the "Company") is pleased to announce that it has satisfied its... ► Artikel lesen | |
| ENTHEON BIOMEDICAL CORP | 0,058 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Execution of Business Combination Agreement with Nutravisor | Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into... ► Artikel lesen | |
| CYBIN | 5,050 | 0,00 % | Jefferies stuft Helus Pharma mit 'Buy' ein und sieht Kurspotenzial von 232 % | ||
| REVIVE THERAPEUTICS | 0,005 | +900,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | Rapid Dose Therapeutics Corp.: Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt | Burlington, Ontario--(Newsfile Corp. - January 5, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that pursuant to the terms of its amended and restated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen |
LOBE SCIENCES LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -6,38 % bei einem Aktienkurs von 0,022 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.